Source comparison
Melanotan-2 Dosing: Research Protocol Comparison
Different research goals require different dosing strategies. The table below compares three common Melanotan-2 protocols based on objective, dose range, frequency, and duration. Conservative Loading 0.25–0.5mg (0.01mg/kg) Daily for 2–3 weeks 14–21 days Gradua
This comparison does not assign a generated winner or score.
- Different research goals require different dosing strategies. The table below compares three common Melanotan-2 protocols based on objective, dose range, frequency, and duration.
- Conservative Loading
- 0.25–0.5mg (0.01mg/kg)
- Daily for 2–3 weeks
- 14–21 days
- Gradual melanogenesis with minimal side effects
- Mild flushing (15–20%), rare nausea
- Best for first-time researchers or those sensitive to MC4R agonists. Slower onset but better tolerability
- Standard Loading
- 0.5–1.0mg (0.015mg/kg)
- Daily for 3–4 weeks
- 21–28 days
- Melanocortin receptor saturation, visible pigmentation within 10–14 days
- Moderate flushing (40–50%), nausea (20–30%), appetite suppression
- Most common research protocol. Balances onset speed with manageable side effects when titrated properly
- Aggressive Loading
- 1.0–2.0mg (0.02mg/kg)
- Daily for 4–6 weeks
- 28–42 days
- Maximal melanogenesis, rapid visible response
- High flushing incidence (60–70%), nausea (40–50%), spontaneous erections (male subjects, 30–40%)
- Used in time-sensitive research or high body weight subjects. Requires strict titration and side effect monitoring
- Maintenance (Post-Loading)
- 0.5–0.7mg (0.01mg/kg)
- 2–3x weekly
- 8–12 weeks
- Sustained melanocortin receptor activation without tachyphylaxis
- Minimal when dosed intermittently. Receptors remain sensitized
- Transition after 3–4 weeks of daily loading. Intermittent dosing prevents receptor desensitization and maintains response
- The Conservative Loading protocol is the entry point for most researchers. It minimizes side effects but extends the time to visible melanogenesis to 14–21 days rather than 7–10 days. Standard Loading represents the evidence-based middle ground. Clinical observations suggest this range produces melanocortin receptor saturation without overwhelming MC4R-mediated nausea in 70–75% of subjects when titrated properly. Aggressive Loading is reserved for high body weight researchers or time-constrained protocols, but the side effect burden is significant enough that 20–30% of researchers reduce dose mid-protocol.
- Maintenance dosing is non-negotiable for protocols extending beyond 4 weeks. Continuous daily dosing past week 4 triggers melanocortin receptor downregulation. The receptors internalize in response to sustained agonist exposure, reducing both melanogenic response and side effect intensity. Intermittent dosing (2–3x weekly) at reduced dose (50–70% of loading dose) preserves receptor sensitivity while maintaining plasma concentrations above the threshold for melanogenesis. Researchers who skip maintenance adjustment report that pigmentation peaks at week 5–6 and plateaus or regresses despite continued dosing.